These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 21595276)

  • 1. [Liraglutide].
    Takahashi T; Odawara M
    Nihon Rinsho; 2011 May; 69(5):883-9. PubMed ID: 21595276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Horowitz M; Flint A; Jones KL; Hindsberger C; Rasmussen MF; Kapitza C; Doran S; Jax T; Zdravkovic M; Chapman IM
    Diabetes Res Clin Pract; 2012 Aug; 97(2):258-66. PubMed ID: 22446097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A; Kapitza C; Hindsberger C; Zdravkovic M
    Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.
    Davies MJ; Kela R; Khunti K
    Diabetes Obes Metab; 2011 Mar; 13(3):207-20. PubMed ID: 21205109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus.
    Drab SR
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):43S-54S. PubMed ID: 19947816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.
    Vilsbøll T; Brock B; Perrild H; Levin K; Lervang HH; Kølendorf K; Krarup T; Schmitz O; Zdravkovic M; Le-Thi T; Madsbad S
    Diabet Med; 2008 Feb; 25(2):152-6. PubMed ID: 18201212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
    Bode B
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2010; 65(7-8):464-70. PubMed ID: 20857706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.
    Flint A; Kapitza C; Zdravkovic M
    Diabetes Obes Metab; 2013 Oct; 15(10):958-62. PubMed ID: 23551925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide: from clinical trials to clinical practice.
    Gough SC
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():33-40. PubMed ID: 22405267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics.
    Jacobsen LV; Flint A; Olsen AK; Ingwersen SH
    Clin Pharmacokinet; 2016 Jun; 55(6):657-72. PubMed ID: 26597252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.
    Vilsbøll T
    Expert Opin Investig Drugs; 2007 Feb; 16(2):231-7. PubMed ID: 17243943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
    Reboldi G
    G Ital Cardiol (Rome); 2009 Jul; 10(7):434-47. PubMed ID: 19761101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
    Nauck MA; Hompesch M; Filipczak R; Le TD; Zdravkovic M; Gumprecht J;
    Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):417-23. PubMed ID: 17039422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
    Ryan GJ; Hardy Y
    J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretins: a new treatment option for type 2 diabetes?
    Geelhoed-Duijvestijn PH
    Neth J Med; 2007 Feb; 65(2):60-4. PubMed ID: 17379930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus.
    Joffe D
    Am J Health Syst Pharm; 2010 Aug; 67(16):1326-36. PubMed ID: 20689121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.